期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
Lipidoid作为新型脂质载体对肝脏非实质细胞的靶向作用实验研究 被引量:1
1
作者 谌双君 郑书全 +8 位作者 赵卫华 范旭 刘天会 王萍 刘涛 郭良霞 高山 尤红 丛敏 《临床和实验医学杂志》 2016年第4期305-309,共5页
目的探讨新型脂质载体Lipidoid对肝脏的细胞靶向效率,为抗肝纤维化治疗提供一定实验室依据。方法C57BL/6小鼠分别给予CCl_4灌胃建立肝纤维化模型,同时给予Lipidoid、Lipidoid/siRNA-TIMP-1尾静脉注射,通过Masson染色观察各组小鼠肝脏纤... 目的探讨新型脂质载体Lipidoid对肝脏的细胞靶向效率,为抗肝纤维化治疗提供一定实验室依据。方法C57BL/6小鼠分别给予CCl_4灌胃建立肝纤维化模型,同时给予Lipidoid、Lipidoid/siRNA-TIMP-1尾静脉注射,通过Masson染色观察各组小鼠肝脏纤维化情况,并通过实时荧光定量PCR和蛋白免疫印迹检测Lipidoid/siRNA-TIMP-1对TIMP-1表达水平的影响;通过对小鼠尾静脉注射绿色荧光(GFP)标记的Lipidoid-GFP,取其肝组织进行冰冻切片分别进行Desmin及F4/80染色,评价Lipidoid-GFP对肝脏非实质细胞的靶向作用;通过对小鼠分离的原代肝星状细胞SW-HSC、小鼠巨噬细胞系(RAW264.7)转染Lipidoid-GFP,流式细胞仪分别检测上述两种细胞中GFP荧光强度。结果通过对肝组织进行Masson染色发现,在CCl_4诱导的肝纤维化小鼠模型中,给予Lipidoid/siRNA-TIMP-1治疗可显著降低胶原纤维的沉积;实时荧光定量PCR和蛋白免疫印迹结果显示Lipidoid/siRNA-TIMP-1可以显著抑制TIMP-1基因的表达;肝组织冰冻切片Desmin及F4/80染色结果显示,Lipidoid-GFP主要被肝脏肝星状细胞和Kuffer所捕获,肝星状细胞、Kuffer细胞捕获Lipidoid-GFP的阳性率分别为13.4%、43.8%;原代肝星状细胞SW-HSC、小鼠巨噬细胞系(RAW264.7)转染Lipidoid-GFP后经流式细胞仪检测,结果显示转染Lipidoid-GFP的SW-HSC及RAW264.7GFP阳性率分别为66.9%、75.8%,均显著高于对照组。结论小鼠实验结果表明,Lipidoid/siRNA-TIMP-1可有效降低肝脏TIMP-1水平,发挥抗肝纤维化作用。Lipidoid作为一种新型脂质载体可有效感染肝脏非实质细胞(肝星状细胞和Kuffer细胞)。 展开更多
关键词 小鼠 肝纤维化 肝脏非实质细胞 脂质载体 lipidoid
下载PDF
let-7a荷载AS1411与lipidoid共修饰阳离子脂质复合物的制备
2
作者 仲婷婷 李言 +4 位作者 高彬彬 李洁琼 Kiramat Ali Shah 曹青日 崔京浩 《当代化工》 CAS 2019年第12期2817-2819,2823,共4页
构建了let-7a荷载AS1411与lipidoid共修饰阳离子脂质复合物,并对其理化性质进行考察。合成荷正电荷类脂质材料N,N’-二油酰三羟甲基氨基甲烷(2-氨基乙基)胺(Lipidoid),然后结合乙醇注入法与静电吸附法,制备荷载let-7a的AS1411与lipidoi... 构建了let-7a荷载AS1411与lipidoid共修饰阳离子脂质复合物,并对其理化性质进行考察。合成荷正电荷类脂质材料N,N’-二油酰三羟甲基氨基甲烷(2-氨基乙基)胺(Lipidoid),然后结合乙醇注入法与静电吸附法,制备荷载let-7a的AS1411与lipidoid共修饰阳离子脂质复合物(let-7a/AS1411-Lipoplex),评价其制剂学性质。通过薄层色谱法(TLC)、核磁共振法(~1H-NMR)、傅里叶转变红外法(FT-IR)和液质联用仪(LC-MS)法验证了Lipidoid的结构。所制得let-7a/AS1411-Lipoplex大小规整,平均粒径为70nm,Zeta电位为30mV,AS1411-Lipoplex明显改善let-7a在血清中降解。成功构建可高效荷载let-7a的适配体(AS1411)与lipidoid共修饰的脂质复合物,为后续研究打下基础。 展开更多
关键词 let-7a 适配体 类脂多胺 阳离子脂质复合物
下载PDF
Study the lipidoid nanoparticle mediated genome editing protein delivery using 3D intestinal tissue model 被引量:1
3
作者 Tao Yang Haobo Han +5 位作者 Ying Chen Liu Yang Rachael Parker Yamin Li David L.Kaplan Qiaobing Xu 《Bioactive Materials》 SCIE 2021年第11期3671-3677,共7页
Lipid nanoparticles are promising carriers for oral drug delivery.For bioactive cargos with intracellular targets,e.g.gene-editing proteins,it is essential for the cargo and carrier to remain complexed after crossing ... Lipid nanoparticles are promising carriers for oral drug delivery.For bioactive cargos with intracellular targets,e.g.gene-editing proteins,it is essential for the cargo and carrier to remain complexed after crossing the epithelial layer of intestine in order for the delivery system to transport the cargos inside targeted cells.However,limited studies have been conducted to verify the integrity of cargo/carrier nanocomplexes and their capability in facilitating cargo delivery intracellularly after the nanocomplex crossing the epithelial barrier.Herein,we used a traditional 2D transwell system and a recently developed 3D tissue engineered intestine model and demonstrated the synthetic lipid nanoparticle(carrier)and protein(cargo)nanocomplexes are able to cross the epithelial layer and deliver the protein cargo inside the underneath cells.We found that the EC16-63 LNP efficiently encapsulated the GFP-Cre recombinase,penetrated the intestinal monolayer cells in both the 2D cell culture and 3D tissue models through temporarily interrupting the tight junctions between epithelial layer.After transporting across the intestinal epithelia,the EC16-63 and GFP-Cre recombinase nanocomplexes can enter the underneath cells to induce gene recombination.These results suggest that the in vitro 3D intestinal tissue model is useful for identifying effective lipid nanoparticles for potential oral drug delivery. 展开更多
关键词 lipidoid nanoparticle Protein delivery Oral drug delivery Genome engineering 3D tissue model
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部